This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The economic analysis included the costs of the programme implementation (opportunity costs for participants and direct expenditure for staff, equipment, supplies, materials, and facilities) and cancer care. Participants' time was estimated using median hourly earnings of women paid hourly rate wages or salaries. The resources for the programme were based on its implementation in the WHI-DM trial. Hourly wages for staff were based on nationally representative rates. Official sources were used for other items. The costs of cancer care were from published studies. The societal perspective included all costs, while the health care payer perspectives excluded opportunity and diet costs. All costs were in US dollars ($) and were discounted at an annual rate of 3%. The price year was 2008.
Analysis of uncertainty:
A Monte Carlo simulation was carried out using predetermined probability distributions for the model inputs to generate confidence intervals around the projected outcomes. One-way sensitivity analyses were carried out on selected model inputs, using authors' assumptions or published ranges of values.
Results
From the societal perspective, the incremental cost-utility ratio (ICUR) of the intervention over usual care was $12,944 in 50-year-old women, and increased consistently with age to $42,842 in 70-year-old women, with a high fat intake. The ICURs in women at a high risk of breast cancer ranged from $10,544 (50 years) to $34,450 (70 years).
From the perspective of the private health care payer, the ICURs were $71,416 for 50-year-olds and $259,286 for 55-year-olds, with a high fat intake, and $47,112 for 50-year-olds and $267,985 for 55-year-olds, at a high risk of breast cancer. From the perspective of Medicare, the ICURs were $14,959 for 65-year-olds and $22,900 for 70-yearolds, with high fat intake, and $11,687 for 65-year-olds and $17,730 for 70-year-olds, at a high risk of breast cancer.
Substantial reductions in the intervention costs (almost 50%) were required for the intervention to be cost saving. The ICURs were considerably lower without discounting. The programme remained cost-effective even if implemented in small groups of participants. The inclusion of participants from randomisation date rather than the intervention start did not change the conclusions.
Authors' conclusions
The authors concluded that the low-fat dietary intervention was cost-effective, for both groups of women, from the perspectives of both society and the public health care payer, but not the private health care payer.
CRD commentary

Interventions:
The selection of the comparators was appropriate and was based on the interventions in the WHI-DM trial. More information on the features of the programme was available in the WHI-DM trial publication.
Effectiveness/benefits:
Most of the clinical inputs were from a large clinical trial that was conducted at several US sites. The details were not reported, but the design should ensure a high internal validity for the data. The clinical trial design was appropriate for assessing a public health intervention, since the sample of participants represented the population that was most likely to benefit from a low-fat diet. The trial was very large and the follow-up was relatively long (eight years). The sources of epidemiological data were representative of the US context and were adjusted where necessary. No information on the derivation of the utility values was provided and the impact of variations in these inputs was not considered in the sensitivity analysis. QALYs were a valid benefit measure because these cancers have a substantial impact on both survival and quality of life.
